Skip to main content
. 2023 Feb 20;7(3):e0057. doi: 10.1097/HC9.0000000000000057

FIGURE 3.

FIGURE 3

Absolute change in score from baseline to week 24 across the PBC-40 domains in patients with mild fatigue at baseline, by treatment arm. (A) Placebo, (B) setanaxib 400 mg OD, (C) setanaxib 400 mg BID. All patients with mild fatigue at baseline and PBC-40 data available at baseline and week 24 were included in these analyses (n=51); some patients may have stopped setanaxib treatment before the end of the treatment period. Reduced scores indicate improvements in symptom impact. Box plots show median (central line) and interquartile range; minimum and maximum values are depicted by vertical whiskers, with outliers indicated by crosses (+). Data labels depict mean (SEM) absolute change from baseline in score for each PBC-40 domain. Tables present mean (SEM) absolute scores in each PBC-40 domain at baseline (BL), week 12 and week 24 by treatment group. Abbreviations: BID, twice daily; OD, once daily; PBC-40, primary biliary cholangitis-40 item questionnaire.